A review of the use of teicoplanin in haematological malignancy

European Journal of Haematology

Volumn 59, Issue SUPPL.62, 1997, Pages 2-5

  Davies, J M ^a  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Haematological malignancy; Non inpatient therapy; Teicoplanin

Indexed keywords

ANTIINFECTIVE AGENT; TEICOPLANIN;

BLOOD DISEASE; HUMAN; OPPORTUNISTIC INFECTION; REVIEW;

ANTI-BACTERIAL AGENTS; HEMATOLOGIC NEOPLASMS; HUMANS; OPPORTUNISTIC INFECTIONS; TEICOPLANIN;

EID: 0031610237     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.1997.tb01701.x     Document Type: Article

References (11)

1. DEL FAVERO A, MENICHETTI F, GUERCIOLINI R, et al. Prospective randomized clinical trial of teicoplanin for empiric combined therapy in febrile, granulocytopenic acute leukemia patients. Antimicrob Agents Chemother 1987: 31: 1126-1129.
2. MARTINO P, MICOZZI A, GENTILE G, RACCAH R, GIRMENIA C, MANDELLI F. Piperacillin plus amikacin vs piperacillin plus amikacin plus teicoplanin for empirical treatment of febrile episodes in neutropenic patients receiving quinolone prophylaxis. Clin Infect Dis 1992: 15: 290-294.
3. MICOZZI A, VENDITTI M, AMADORI S, PULSONI A, TIRINDELLI C, MARTINO P. Teicoplanin in the treatment of Gram-positive bacteraemia in neutropenic patients. Br J Haematol 1990: 76 (suppl 2): 19-23.
4. MENICHETTI F, MARTINO P, BUCANEVE G, et al. AND THE GIMEMA INFECTION PROGRAM. Effects of teicoplanin and those of vancomycin in initial empirical antibiotic regimen for febrile, neutropenic patients with hematologic malignancies. Antimicrob Agents Chemother 1994: 38: 2041-2046.
5. KUREISHI A, JEWESSON PJ, RUBINGER M, et al. Double-blind comparison of teicoplanin versus vancomycin in febrile neutropenic patients receiving concomitant tobramycin and piperacillin: effect on cyclosporin A-associated nephrotoxicity. Antimicrob Agents Chemother 1991: 35: 2246-2252.
6. SMITH SR, CHEESBROUGH J, SPEARING R, DAVIES JM. Randomized prospective study comparing vancomycin with teicoplanin in the treatment of Gram-positive coccal infections in cancer patients: early termination due to emergence of resistance to fluoroquinolones. Support Care Cancer 1994: 2: 191-196.
7. WEBSTER A, RUSSELL SJ, SOUHAMI RL, RICHARDS JDM, GOLDSTONE AH, GRUNEBERG RN. Use of teicoplanin for Hickman catheter associated infection in immunocompromised patients. J Hosp Infect 1987: 10: 77-82.
8. CONY-MAKHOUL P, BROSSARD G, MARIT G, PELLFGRIN JL, TEXIER-MAUGEIN J, REIFFERS J. A prospective study comparing vancomycin and teicoplanin as second-line empiric therapy for infection in neutropenic patients. Br J Haematol 1990: 76 (suppl 2): 35-40.
9. AVRIL M, HARTMANN O, VALTEAU-COUANET D, BRUGIERES L, KALIFA C, LEMERLE J. Antiinfective prophylaxis with ceftazidime and teicoplanin in children undergoing highdose chemotherapy and bone marrow transplantation. Pediatr Hematol Oncol 1994: 11: 63-73.
10. Guidelines on the management of tunnelled central venous lines. Clinical Haematology Task Force of the British Committee for Standards in Hematology (in press).
11. CHOI JK, KIM YR, SHIN WS, et al. A randomized study comparing clinical efficacy of ceftazidime plus aztreonam plus teicoplanin or vancomycin containing regimen in febrile granuloctopenic patients. J Korean Soc Chemother 1992: 10: 165-171.